Education
About Us
Working with TipRanks
Follow Us
Brainsway (BWAY)
NASDAQ:BWAY
BWAY Stock Chart & Stats
$22.56
-$0.11(-1.13%)
At close: 4:00 PM EST
$22.56
-$0.11(-1.13%)
Day’s Range― - ―
52-Week Range$7.84 - $25.65
Previous CloseN/A
Volume9.67K
Average Volume (3M)106.68K
Market Cap
$459.83M
Enterprise Value$395.59M
Total Cash (Recent Filing)$70.46M
Total Debt (Recent Filing)$6.75M
Price to Earnings (P/E)67.6
Beta1.46
Next Earnings
Mar 11, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding19,608,213
10 Day Avg. Volume94,412
30 Day Avg. Volume106,683
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)2.57
Price to Sales (P/S)3.90
P/FCF Ratio24.63
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue8.06
Enterprise Value/Gross Profit10.76
Enterprise Value/Ebitda43.40
Forecast
1Y Price Target
$26.33Price Target Upside16.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.27
Revenue Forecast (FY)$64.81M
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalFDA approval of Neurolief ProlivRx for at-home use positions the company as the first at-home neuromodulation option for treatment‑refractory major depressive disorder, expanding the addressable market and supporting higher analyst valuation.
Reimbursement And Commercial AdoptionReimbursement wins and growing acceptance of pay‑per‑use models improve revenue prospects for Deep TMS solutions and increase the feasibility of wider clinical adoption.
Strategic Acquisition And InvestmentOption to acquire Neurolief combined with an initial strategic investment gives the company a clear pathway to add at-home neuromodulation capabilities, supporting product ecosystem expansion and potential cross-selling with Deep TMS.
Bears Say
Brainsway News
BWAY FAQ
What was Brainsway’s price range in the past 12 months?
Brainsway lowest stock price was $7.84 and its highest was $25.65 in the past 12 months.
What is Brainsway’s market cap?
Brainsway’s market cap is $459.83M.
When is Brainsway’s upcoming earnings report date?
Brainsway’s upcoming earnings report date is Mar 11, 2026 which is in 27 days.
How were Brainsway’s earnings last quarter?
Brainsway released its earnings results on Nov 11, 2025. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.047 by -$0.007.
Is Brainsway overvalued?
According to Wall Street analysts Brainsway’s price is currently Undervalued.
Does Brainsway pay dividends?
Brainsway does not currently pay dividends.
What is Brainsway’s EPS estimate?
Brainsway’s EPS estimate is 0.05.
How many shares outstanding does Brainsway have?
Brainsway has 19,608,213 shares outstanding.
What happened to Brainsway’s price movement after its last earnings report?
Brainsway reported an EPS of $0.04 in its last earnings report, missing expectations of $0.047. Following the earnings report the stock price went down -5.831%.
Which hedge fund is a major shareholder of Brainsway?
Currently, no hedge funds are holding shares in BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Brainsway Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.33 (16.71% Upside)
$26.33 (16.71% Upside)
Blogger Sentiment
Bullish
BWAY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 199.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
119.88%
12-Months-Change
Fundamentals
Return on Equity
11.05%
Trailing 12-Months
Asset Growth
56.81%
Trailing 12-Months
Company Description
Brainsway
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BWAY Company Deck
BWAY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
BrainsWay's Q3 2025 earnings call indicated strong growth and positive developments, including record revenue, increased system shipments, and successful strategic investments. Despite increased operating expenses and a delay in FDA clearance for Neurolief, the company's performance and raised guidance reflect a generally optimistic outlook.View all BWAY earnings summariesBWAY Stock 12 Month Forecast
Average Price Target
$26.33
▲(16.71% Upside)
Technical Analysis
Sanuwave Health
―
Tactile Systems Technology
―
Viemed Healthcare
―
TriSalus Life Sciences
―
NeuroPace
―
Ownership Overview
―
Insiders
0.89% Mutual Funds
19.85% Other Institutional Investors
78.52% Public Companies and
Individual Investors